Log in using your username and password
Registration is Now Required for Free Access
to CCJM Content
Register once and log in for full access to articles and content. Click “Register” in the upper right corner and follow the simple instructions to create a new account.
If you are using a mobile device, click on the settings icon to access the Register link.
Click on the link below to see a list of our CME/MOC articles.
Heart failure guidelines: What you need to know about the 2017 focused update
Jump to section
- Article
- ABSTRACT
- COMMON, COSTLY, AND DEBILITATING
- BIOMARKERS FOR PREVENTION
- BIOMARKERS FOR PROGNOSIS OR ADDED RISK STRATIFICATION
- PHARMACOLOGIC TREATMENT FOR STAGE C HFpEF
- ALDOSTERONE ANTAGONISTS FOR HFpEF
- IRON DEFICIENCY IN HEART FAILURE
- HYPERTENSION IN HEART FAILURE
- SLEEP-DISORDERED BREATHING IN HEART FAILURE
- POTENTIAL APPLICATIONS IN ACUTE DECOMPENSATED HEART FAILURE
- SHOULD WE USE BIOMARKER TARGETS TO GUIDE THERAPY IN ADHF?
- SHOULD ALDOSTERONE ANTAGONISTS BE USED IN ACUTE HFpEF?
- SHOULD INTRAVENOUS IRON BE GIVEN DURING ADHF ADMISSIONS?
- INTERNISTS ARE KEY
- Footnotes
- REFERENCES
- Figures & Data
- Info & Metrics
Related Articles
Cited By...
- No citing articles found.